The potential for improving cardio-renal outcomes in chronic kidney disease with the aldosterone synthase inhibitor vicadrostat (BI 690517): a rationale for the EASi-KIDNEY trial
A commentary from the ERBP on the KDIGO 2024
ERBP - European Renal Best Practice
A commentary from the European Renal Best Practice (ERBP) on the Kidney Disease Improving Global Outcomes (KDIGO) 2024 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease in children and adults
Access paper
Speaker
Charles Ferro, United Kingdom
Panellists
Mehmet Kanbay, Türkiye
Valerie Luyckx, Switzerland
Moderator
Pantelis Sarafidis, Greece